Boston Scientific Corporation has announced the pricing of €1.5 billion in senior notes through its wholly owned finance subsidiary, American Medical Systems Europe B.V. The issuance includes €850 million of 3.000% notes due 2031 and €650 million of 3.250% notes due 2034. The offering is expected to close on February 26, 2025, subject to customary conditions. The proceeds, combined with cash on hand, will be used to repay AMS Europe's 0.750% senior notes due March 8, 2025, and for general corporate purposes, including short-term investments, debt reduction, working capital, and potential acquisitions.